標(biāo)題: Titlebook: Nonanticoagulant Actions of Glycosaminoglycans; Job Harenberg,Benito Casu Book 1996 Plenum Press, New York 1996 Alzheimer.Oligosaccharid.b [打印本頁(yè)] 作者: ambulance 時(shí)間: 2025-3-21 20:08
書目名稱Nonanticoagulant Actions of Glycosaminoglycans影響因子(影響力)
書目名稱Nonanticoagulant Actions of Glycosaminoglycans影響因子(影響力)學(xué)科排名
書目名稱Nonanticoagulant Actions of Glycosaminoglycans網(wǎng)絡(luò)公開(kāi)度
書目名稱Nonanticoagulant Actions of Glycosaminoglycans網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書目名稱Nonanticoagulant Actions of Glycosaminoglycans被引頻次
書目名稱Nonanticoagulant Actions of Glycosaminoglycans被引頻次學(xué)科排名
書目名稱Nonanticoagulant Actions of Glycosaminoglycans年度引用
書目名稱Nonanticoagulant Actions of Glycosaminoglycans年度引用學(xué)科排名
書目名稱Nonanticoagulant Actions of Glycosaminoglycans讀者反饋
書目名稱Nonanticoagulant Actions of Glycosaminoglycans讀者反饋學(xué)科排名
作者: Exaggerate 時(shí)間: 2025-3-21 20:49
Protein Binding of Sulfated Glycosaminoglycans,mal tissues and in cell surfaces as proteoglycans, i.e., as polysaccharide chains covalently attached, comb-like, to serine residues of polypeptide chains. The number and length of GAG chains linked to the polypetide matrices varies for different proteoglycans, and for the same proteoglycan in different cells..作者: 歸功于 時(shí)間: 2025-3-22 01:31
Book 1996uring the last 50 years. However, its potential side effects have led to the search for equally effective but safer alternatives. At present, the low-molecular-weight heparins are the most promising steps in this direction. Considerable interest has been generated at the same time in exploring other作者: Nerve-Block 時(shí)間: 2025-3-22 05:14
ive drug during the last 50 years. However, its potential side effects have led to the search for equally effective but safer alternatives. At present, the low-molecular-weight heparins are the most promising steps in this direction. Considerable interest has been generated at the same time in explo作者: Restenosis 時(shí)間: 2025-3-22 08:55
Application of Mass Spectrometry to the Analysis of Natural and Synthetic Sulfated Oligosaccharidesthe development of refined techniques of carbohydrate synthesis (5) opened up the possibility to produce synthetic sulfated oligosaccharides; some of them presenting relevant pharmacological activities (6).作者: Chipmunk 時(shí)間: 2025-3-22 16:01 作者: FACT 時(shí)間: 2025-3-22 20:03
Monoclonal Antibody Directed Against Heparin and Heparin-Fractions,sulfate, dermatan sulfate, chondroitin sulfate A and C. Oversulfated heparin showed lower affinity to the antibody H 1.18 than 2–0-and 6–0-desulfated heparin..In conclusion, the present paper describes an IgG 1 monoclonal directed against heparin fractions between 4.500 and 6.500 dalton, which can be used for biological measurements.作者: infringe 時(shí)間: 2025-3-23 00:56
Non-Anticoagulant Actions of Glycosaminoglycans,c saccharide sequence,. that is present in approximately one-third of the molecules of commercial UFH,. while the non-specific binding of UFH to the other plasma proteins appears to be related to heparin molecular size, the higher molecular weight chains showing a greater affinity binding than those of lower molecular weight..作者: arboretum 時(shí)間: 2025-3-23 02:19
New NMR Spectroscopic Approaches for Structural Analysis of Glycosaminoglycans,Nuclear Magnetic Resonance (NMR) spectra provide detailed information on the structure and interactions of molecules, mainly because a molecular system gives signals at different frequency values as a function of the type and molecular environment of magnetically active nuclei.作者: Inclement 時(shí)間: 2025-3-23 06:29 作者: Obsessed 時(shí)間: 2025-3-23 11:07 作者: Osteoarthritis 時(shí)間: 2025-3-23 17:32
http://image.papertrans.cn/n/image/667162.jpg作者: dysphagia 時(shí)間: 2025-3-23 21:03 作者: STEER 時(shí)間: 2025-3-24 02:13 作者: 潰爛 時(shí)間: 2025-3-24 05:16 作者: 神圣將軍 時(shí)間: 2025-3-24 09:17 作者: indigenous 時(shí)間: 2025-3-24 13:51 作者: sinoatrial-node 時(shí)間: 2025-3-24 15:04 作者: Bricklayer 時(shí)間: 2025-3-24 21:08 作者: Breach 時(shí)間: 2025-3-25 02:05 作者: EWER 時(shí)間: 2025-3-25 06:53
Marco Rusnati,D. Coltrini,Pasqua Oreste,Giorgio Zoppetti,Marco Prestathogenic FR-positive diseases, including cancer. Since the FR transports folates via a low capacity but high affinity endocytic pathway, a variety of FR-targeted antifolate drugs and folate conjugates bearing a978-1-4899-8886-7978-1-4419-8417-3作者: 嘲笑 時(shí)間: 2025-3-25 08:13
Laura Giorgini,Annamaria Naggi,Giancarlo Ghisellithogenic FR-positive diseases, including cancer. Since the FR transports folates via a low capacity but high affinity endocytic pathway, a variety of FR-targeted antifolate drugs and folate conjugates bearing a978-1-4899-8886-7978-1-4419-8417-3作者: foreign 時(shí)間: 2025-3-25 12:31 作者: Filibuster 時(shí)間: 2025-3-25 16:28 作者: obstruct 時(shí)間: 2025-3-25 23:42
Piotr Radziwon,J. Schenk,B. Boczkowska-Radziwon,Jawed Fareed,Hans K. Breddin作者: 外表讀作 時(shí)間: 2025-3-26 01:28
Susanne Alban,Walter Jeske,Debra Hoppensteadt,Jawed Fareed,Gerhard Franz作者: 粗糙 時(shí)間: 2025-3-26 05:32 作者: tenosynovitis 時(shí)間: 2025-3-26 11:50 作者: Physiatrist 時(shí)間: 2025-3-26 16:33 作者: Hemodialysis 時(shí)間: 2025-3-26 17:20
Günter Huhle,Job Harenberg,Reinhard Malsch,Dieter L. Heene diseases. High affinity folate-radioisotope conjugates have been developed for imaging pathogenic FR-positive diseases, including cancer. Since the FR transports folates via a low capacity but high affinity endocytic pathway, a variety of FR-targeted antifolate drugs and folate conjugates bearing a作者: Electrolysis 時(shí)間: 2025-3-26 22:02 作者: 割讓 時(shí)間: 2025-3-27 04:35 作者: savage 時(shí)間: 2025-3-27 08:30
Kevin R. Holme,Weisheng Liang,Zicheng Yang,France Lapierre,Patrick N. Shaklee,Lun Lam diseases. High affinity folate-radioisotope conjugates have been developed for imaging pathogenic FR-positive diseases, including cancer. Since the FR transports folates via a low capacity but high affinity endocytic pathway, a variety of FR-targeted antifolate drugs and folate conjugates bearing a作者: 截?cái)?nbsp; 時(shí)間: 2025-3-27 10:36
Roger A. Laine diseases. High affinity folate-radioisotope conjugates have been developed for imaging pathogenic FR-positive diseases, including cancer. Since the FR transports folates via a low capacity but high affinity endocytic pathway, a variety of FR-targeted antifolate drugs and folate conjugates bearing a作者: 褪色 時(shí)間: 2025-3-27 16:22 作者: 招人嫉妒 時(shí)間: 2025-3-27 19:23 作者: Blatant 時(shí)間: 2025-3-28 00:35
Intact Biological Activity and Binding to Granulocytes of LMM-Heparin-Tyramine-Fitc, 5). This technique should provide an intact binding site of the LMM-Heparin to the binding sequences on proteins. Beside the anticoagulant activity, many non-anticoagulant activities of heparin are of clinical relevance (6). These may be induced by the binding of heparin to the endothelium, erythro作者: 鴕鳥 時(shí)間: 2025-3-28 05:27
A Detailed Evaluation of the Structural and Biological Effects of Alkaline O-Desulfation Reactions ree of polymerization). The well characterized pentasaccharide sequence responsible for the heparin-antithrobin III (ATIII) interaction,. and the minimal hexasaccharide sequence responsible for the heparin-bFGF interaction. are examples of interactions or activities of heparin mediated by specific o作者: 航海太平洋 時(shí)間: 2025-3-28 06:25
The Interaction of Basic Fibroblast Growth Factor (bFGF) With Heparan Sulfate Proteoglycans,ntracellular fate of bFGF, suggesting that bFGF-HSPGs complexes are involved in the intracellular delivery of bFGF. It derives that the bioavailability and the biological activity of bFGF strictly depend on the glycosaminoglycan milieu of the extracellular environment, indicating the possibility to 作者: anchor 時(shí)間: 2025-3-28 12:45
Binding of 125I-bFGF to Rat Aortic Smooth Muscle Cells,able results. The data presented are consistent with the concepts that: 1) specific structural features are involved in the interaction of SMC glycosaminoglycans with .I-bFGF, and 2) antimitogenic activity of heparin has structural requirements different than those for bFGF binding.作者: jealousy 時(shí)間: 2025-3-28 16:57 作者: BOOR 時(shí)間: 2025-3-28 22:12 作者: 難理解 時(shí)間: 2025-3-29 01:39 作者: inflame 時(shí)間: 2025-3-29 04:26 作者: 投射 時(shí)間: 2025-3-29 10:06 作者: vector 時(shí)間: 2025-3-29 11:32 作者: 大喘氣 時(shí)間: 2025-3-29 16:53 作者: vertebrate 時(shí)間: 2025-3-29 23:48 作者: DENT 時(shí)間: 2025-3-30 01:46
Luigi Silvestro,Simona Rizea Savu,P. A. van Veelen,P. L. Jacobs what’s considered to be “molecular targeted” versus convent.Folate pathways are essential in metabolism and macromolecule synthesis. Antifolate drugs that are largely transported via a high capacity folate transporter (i.e. the reduced-folate carrier) and inhibit folate-dependent enzymes include th作者: comely 時(shí)間: 2025-3-30 06:54
Günter Huhle,Job Harenberg,Reinhard Malsch,Dieter L. Heenensporter (i.e. the reduced-folate carrier) and inhibit folate-dependent enzymes include the dihydrofolate reductase inhibitor, methotrexate, and the thymidylate synthase inhibitors, raltitrexed and pemetrexed. Major advances in folate research made within the last decade include (i) the approval of 作者: 策略 時(shí)間: 2025-3-30 10:41 作者: 無(wú)表情 時(shí)間: 2025-3-30 15:21 作者: interrupt 時(shí)間: 2025-3-30 16:49
Benito Casu what’s considered to be “molecular targeted” versus convent.Folate pathways are essential in metabolism and macromolecule synthesis. Antifolate drugs that are largely transported via a high capacity folate transporter (i.e. the reduced-folate carrier) and inhibit folate-dependent enzymes include th作者: 使?jié)M足 時(shí)間: 2025-3-30 22:53 作者: miscreant 時(shí)間: 2025-3-31 02:39 作者: 搬運(yùn)工 時(shí)間: 2025-3-31 06:07 作者: 平庸的人或物 時(shí)間: 2025-3-31 11:40
Kevin R. Holme,Weisheng Liang,Zicheng Yang,France Lapierre,Patrick N. Shaklee,Lun Lamnsporter (i.e. the reduced-folate carrier) and inhibit folate-dependent enzymes include the dihydrofolate reductase inhibitor, methotrexate, and the thymidylate synthase inhibitors, raltitrexed and pemetrexed. Major advances in folate research made within the last decade include (i) the approval of 作者: ADOPT 時(shí)間: 2025-3-31 16:02
Roger A. Lainensporter (i.e. the reduced-folate carrier) and inhibit folate-dependent enzymes include the dihydrofolate reductase inhibitor, methotrexate, and the thymidylate synthase inhibitors, raltitrexed and pemetrexed. Major advances in folate research made within the last decade include (i) the approval of 作者: G-spot 時(shí)間: 2025-3-31 19:12
Marco Rusnati,D. Coltrini,Pasqua Oreste,Giorgio Zoppetti,Marco Presta what’s considered to be “molecular targeted” versus convent.Folate pathways are essential in metabolism and macromolecule synthesis. Antifolate drugs that are largely transported via a high capacity folate transporter (i.e. the reduced-folate carrier) and inhibit folate-dependent enzymes include th作者: Free-Radical 時(shí)間: 2025-4-1 00:35
Laura Giorgini,Annamaria Naggi,Giancarlo Ghiselli what’s considered to be “molecular targeted” versus convent.Folate pathways are essential in metabolism and macromolecule synthesis. Antifolate drugs that are largely transported via a high capacity folate transporter (i.e. the reduced-folate carrier) and inhibit folate-dependent enzymes include th作者: exophthalmos 時(shí)間: 2025-4-1 04:11
Giovanni Camussi,E. Battaglia,Enrico Lupia,G. Montrucchiosignificant therapeutic challenge. LR is one of the most common forms of relapse after conventional treatment of CRC. LR significantly worsens the prognosis and constitutes one of the major causes of CRC treatment failure. Long-term local control and survival rates vary from 41 to 77 % and from 1 to作者: Anguish 時(shí)間: 2025-4-1 07:59
